Danaher (DHR) Price & Analysis
DHR Stock Chart & Stats
- Day’s Range
- MXN 4,312.78 - MXN 4,460.00
- 52-Week Range
- MXN 2,760.00 - MXN 4,600.00
- Previous Close
- MXN 4,460.00
- Volume
- 38
- Average Volume (3M)
- 188
- Market Cap
- MXN 3.07T
- Enterprise Value
- MXN 180.78B
- Total Cash (Recent Filing)
- MXN 5.68B
- Total Debt (Recent Filing)
- MXN 26.48B
- Price to Earnings (P/E)
- 37.9
- Beta
- 0.02
- Next Earnings
- Jan 27, 2027
- EPS Estimate
- 45.94
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.61%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Danaher’s substantial operating and free cash flow provides internal funding for innovation, acquisitions, debt service, and shareholder returns. Strong conversion of earnings into cash also supports resilience through cyclical laboratory and bioprocessing demand, while reducing reliance on external financing.
Recurring Consumables And Services Model
Danaher combines instruments with recurring consumables, reagents, software, and aftermarket services. This installed-base model deepens customer relationships, creates repeat purchasing, and can make revenue more durable than a business dependent only on episodic capital-equipment sales.
AI And Automation Platform Expansion
The autonomous-lab initiative broadens Danaher’s role from selling individual tools to enabling integrated research workflows. Combining instruments, consumables, robotics, software, and AI could improve customer productivity, increase platform pull-through, and create durable differentiation in scientific automation.
Bears Say
Respiratory Revenue Volatility
Respiratory exposure remains a meaningful source of revenue volatility because demand is influenced by infection rates and flu-season variability. Continued weakness can suppress Diagnostics growth and make consolidated performance less representative of underlying trends in other businesses.
Modest Growth And Lower Profitability
Recent growth has not fully reflected the portfolio’s potential, and profitability remains below prior peak levels. A slower revenue trajectory can limit operating leverage, while the margin reset reduces earnings cushion and makes sustained acceleration more important to future performance.
Higher Leverage Reduces Flexibility
Higher leverage leaves Danaher with less financial flexibility than in prior years, even though equity remains substantial. Additional debt can increase interest and refinancing exposure, constrain acquisition capacity, and reduce room to respond aggressively if end-market conditions weaken.
Danaher News
DHR FAQ
What was Danaher’s price range in the past 12 months?
What is Danaher’s market cap?
When is Danaher’s upcoming earnings report date?
How were Danaher’s earnings last quarter?
Is Danaher overvalued?
Does Danaher pay dividends?
What is Danaher’s EPS estimate?
How many shares outstanding does Danaher have?
What happened to Danaher’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Danaher?
What is the TipRanks Smart Score and how is it calculated?
Danaher Stock Smart Score
Company Description
Danaher
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Julie Sawyer Montgomery
- Employees
- 59,000
- Website
- www.danaher.com
- Address
- 2200 Pennsylvania Avenue, NW, Washington, DC, 20037-1701, US
Danaher (DHR) Earnings & Revenues
DHR Company Deck
DHR Earnings Call
Earnings Call SentimentPositive
The call was broadly positive. Danaher delivered better-than-expected revenue, earnings, margins, and cash flow; raised full-year EPS guidance; reported improving trends across biotechnology, life sciences, and diagnostics; and highlighted strong orders, AI initiatives, and acquisition integration. The main challenges were respiratory-related revenue declines, North American weakness, academic and selected discovery-market softness, and a measured 4%-5% initial 2027 growth framework. Highlights significantly outweighed the lowlights.
View all MX:DHR earnings summariesDHR Net sales Breakdown
- 29.68% Biotechnology
- 29.85% Life Sciences
- 40.46% Diagnostics
DHR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |